Price movement over the last 24 hours
Alcon AG vs KB Financial Group, Inc. — how do they compare? Alcon AG trades at $66.97 (market cap $32.69B), while KB Financial Group, Inc. trades at $114.66 (market cap $39.97B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ALC | KB | |
|---|---|---|
Market Cap | $32.69B | $39.97B |
Sector | Health | Financials |
52-Week High | $92.22 | $118.21 |
52-Week Low | $62.02 | $77.50 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 2.72% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
KB trades at $115.48, up 5.61% today, showing strong momentum near its 52-week high. Recent quarters have consistently beaten earnings expectations, with Q1 2026 EPS of $3.49 surpassing estimates. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth to $21.23T in 2025 and a healthy net income margin of 27.82%.
Outlook remains positive given earnings beats and valuation appeal with a P/E of 10.95, though risks include volatile cash flows and high interest expenses. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism for continued performance if execution aligns with growth targets.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →